The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two ...

The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of ...

There has been no shortage of news covered across the diabetes and drug delivery markets over the course of 2024.

The investment comes as part of a new health monitoring partnership between the continuous glucose monitor (CGM) maker and Oura, the maker of smart ring technology. Fidelity Management & Research Co.

Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP ...

Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership ...

Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose ...

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading platforms, with ...

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform.